CMS

Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation

Retrieved on: 
Monday, March 25, 2024
OSA, Growth, Otorhinolaryngology, Partnership, Patient, Mont-Saint-Guibert, Insurance, Euronext, AAO, Obstructive sleep apnea, CMS, Corporation, Pharmaceutical industry

Nyxoah is the first medical device company to partner with the AAO-HNSF at this level.

Key Points: 
  • Nyxoah is the first medical device company to partner with the AAO-HNSF at this level.
  • The AAO-HNSF is committed to identifying and combating harmful coverage policies that threaten access to quality otolaryngology-head and neck services.
  • The Academy’s Advocacy team, in collaboration with its dedicated members and strategic industry partners like Nyxoah, actively engage with payers to achieve this goal.
  • “Nyxoah and the AAO-HNSF share the common goal of putting patients first and making sure they have access to HGNS therapy.

Congress Passes Bills Making Major Investments in Alzheimer’s

Retrieved on: 
Saturday, March 23, 2024
Congress, Medical imaging, Caregiver, Health equity, DSM-IV codes, Research, National Institute on Aging, National coverage determination, Investment, CDC, NINDS, Language, Dementia, NIA, Medicare, NCD, CMS, Pharmaceutical industry

WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.

Key Points: 
  • WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.
  • “We are thrilled to witness Congress’s steadfast 12-year commitment to Alzheimer’s research, despite ongoing budget restraints,” said UsAgainstAlzheimer’s chair and co-founder George Vradenburg.
  • UsAgainstAlzheimer’s worked to include language encouraging diversity in clinical trials, and the establishment of a brain health equity initiative to improve the integration of brain health into primary care, particularly within underrepresented communities.
  • The bill also encourages the National Institute of Biomedical Imaging and Bioengineering to collaborate with National Institute of Aging (NIA) and The National Institute of Neurological Disorders and Stroke (NINDS) to develop new technologies that could discover the earliest biological events that lead to Alzheimer’s disease and related dementias.

ADAPTHEALTH ALERT: Bragar Eagel & Squire, P.C. is Investigating AdaptHealth Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 22, 2024
Sleep apnea, Diabetes, Telephone, Patient, Insurance, Complaint, P.C, Medicare, CMS, Cryptocurrency

Our investigation concerns whether the board of directors of AdaptHealth have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of AdaptHealth have breached their fiduciary duties to the company.
  • AdaptHealth is a supplier of home medical equipment for chronic health conditions including diabetes, sleep apnea, and wound care.
  • AdaptHealth sells medical devices directly to patients, and then bills patients’ insurance providers, including the Centers for Medicare and Medicaid Services (“CMS”).
  • To facilitate this scheme, AdaptHealth and certain of its senior executives made numerous false and misleading statements to investors during the Class Period.

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 21, 2024
Burn, Tax, Debridement, Patient, EWMA, Bank statement, Eschar, Investment, SAWC, Therapy, Depreciation, European Commission, Phase, BCC, Research, Supplement, Wound, EMA, GMP, HERE, Safety, CMS, BLA, Eastern Time Zone, Food, Bromelain (pharmacology), WBP, Development, PMI, WHS, Adjustment, FDA, BMCI, Forecasting, Symposium, Incidence, BSV, Basal-cell carcinoma, Operating cost, European Wound Management Association, Table, Event, Medicare, Pharmaceutical industry

YAVNE, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Revenue: Revenue for the fourth quarter 2023 was $5.3 million, compared to $11.6 million in the fourth quarter of 2022.
  • Research and development expenses in the fourth quarter 2023 were $1.8 million compared to $2.7 million in the fourth quarter of 2022.
  • Selling, general, and administrative expenses in the fourth quarter 2023 were $2.8 million, compared to $3.0 million in the fourth quarter of 2022.
  • Operating Results: Operating loss in the fourth quarter of 2023 was $3.9 million, compared to an operating profit of $2.1 million in the fourth quarter of 2022.

Inovalon Announces Converged Submissions To Support Health Plan Risk Adjustment Programs

Retrieved on: 
Monday, March 18, 2024
ACA, Algorithm, Software as a service, Health, Risk, Converge, HHS, Human services, Medicare, CMS, Risk management

BOWIE, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Inovalon , a leading provider of cloud-based software solutions empowering data-driven healthcare, launched Converged Submissions today to simplify and improve encounter data submissions in support of risk adjustment programs.

Key Points: 
  • BOWIE, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Inovalon , a leading provider of cloud-based software solutions empowering data-driven healthcare, launched Converged Submissions today to simplify and improve encounter data submissions in support of risk adjustment programs.
  • This cloud-based SaaS solution is part of Inovalon's Converged Risk Solution Suite and analyzes encounter data to determine risk adjustment eligibility and deliver complete and accurate encounter data submissions on demand.
  • "Health plans need insights into the complex risk adjustment submissions process and solutions that adhere to CMS regulations.
  • For more information on Converged Submissions, go to inovalon.com/encounter-submissions , and visit Inovalon at RISE National Booth #405 in Nashville, TN.

Noridian Continues To Support Providers and Suppliers Amid Change Healthcare Cyber Security Incident

Retrieved on: 
Thursday, March 14, 2024
American Samoa, DME, Change Healthcare, Senior, Medicare, CMS, Health insurance

FARGO, N.D., March 14, 2024 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, is providing billing and claims processing support to providers impacted by the repercussions of the recent Change Healthcare cyber security incident.

Key Points: 
  • FARGO, N.D., March 14, 2024 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, is providing billing and claims processing support to providers impacted by the repercussions of the recent Change Healthcare cyber security incident.
  • In collaboration with the Centers for Medicare & Medicaid Services (CMS), Noridian is offering multiple options for navigating billing challenges, including electronic workarounds.
  • Additionally, Noridian streamlines the process for requesting Accelerated and Advance Payments to provide financial relief to impacted providers.
  • Through collaborative efforts with the CMS and other stakeholders, Noridian is working to facilitate options to resolve the ongoing challenges posed by Change Healthcare’s cyber security incident.

Canada’s Premier Music Media Outlet, Exclaim!, Upgrades to Modern Website Platform Powered by 9thCO

Retrieved on: 
Wednesday, March 13, 2024
Vox Media, Exclaim!, The Washington Post, Architecture, CMS, Growth, Next.js, API, Video game

The new website, exclaim.ca, leverages cutting-edge composable architecture, powered by a headless CMS and Next.js, to deliver a significantly improved user experience, enhanced flexibility, and future-proof scalability.

Key Points: 
  • The new website, exclaim.ca, leverages cutting-edge composable architecture, powered by a headless CMS and Next.js, to deliver a significantly improved user experience, enhanced flexibility, and future-proof scalability.
  • Prior to the upgrade, Exclaim's website was built on a traditional platform that limited its ability to adapt to changing user needs and market trends.
  • This allows for greater flexibility and customization, as content can be easily delivered to any device or platform through APIs.
  • "The new website is a testament to the power of composable architecture and the benefits it can deliver to modern businesses.

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Retrieved on: 
Tuesday, March 12, 2024
BCDA, Patient, Mortality, Quality of life, Therapy, LVAD, Medicare, FDA, CMS, Arrest, Heart failure, Pharmaceutical industry

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage.

Key Points: 
  • CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage.
  • The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers.
  • “We are pleased that CMS has provided coverage support for the confirmatory CardiAMP Heart Failure II study.” said Peter Altman, PhD., BioCardia’s President and Chief Executive Officer.
  • “To my knowledge, no therapy has been proven to reduce mortality in these patients, and CardiAMP Heart Failure II has great potential to achieve this outcome by confirming our CardiAMP Heart Failure Trial results.”

CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 12, 2024
Kidney, Drug, Patient, ESRD, Prospective payment system, NDA, Investment, Annual report, Medicare, FDA, CMS, Hand

CorMedix’s TDAPA application remains under review, and CMS has confirmed that it is working toward a July 1st effective implementation for TDAPA.

Key Points: 
  • CorMedix’s TDAPA application remains under review, and CMS has confirmed that it is working toward a July 1st effective implementation for TDAPA.
  • Pending a timely implementation of TDAPA, CorMedix intends to launch in the outpatient setting in July 2024.
  • Operating expenses during the fourth quarter of 2023 were $15.7 million, compared with $8.4 million in the fourth quarter of 2022, an increase of approximately $7.3 million.
  • The management team of CorMedix will host a conference call and webcast today, March 12, 2023, at 8:30 AM Eastern Time, to discuss recent corporate developments and financial results.

Mark Farrah Associates Simplifies Analysis of the Medicare Advantage and Prescription Drug Plan Senior Markets

Retrieved on: 
Friday, April 5, 2024
Professional Services, Public Policy, Government, Health, Healthcare Reform, Insurance, Health Insurance, Finance, PDP, MBO, Medicare, Data, MFA, CMS

Mark Farrah Associates’ (MFA), www.markfarrah.com , Medicare Business Online™ (MBO) product simplifies the analysis and tracking of Medicare Advantage (MA) and stand-alone Prescription Drug Plan (PDP) enrollment by health plan as released by the Centers for Medicare & Medicaid Services (CMS).

Key Points: 
  • Mark Farrah Associates’ (MFA), www.markfarrah.com , Medicare Business Online™ (MBO) product simplifies the analysis and tracking of Medicare Advantage (MA) and stand-alone Prescription Drug Plan (PDP) enrollment by health plan as released by the Centers for Medicare & Medicaid Services (CMS).
  • Easy-to-navigate tables with download to Excel functionality allow for swift monitoring of competitive positions in the MA and stand-alone PDP senior markets.
  • Data is organized at national, state, and county levels and is aggregated by parent, contract, and plan.
  • Trend data for Medicare Eligibles and current enrollment for Original Medicare are also featured.